Home > Insider Trading > Filing (0001127602-20-031626)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1703647	Frequency Therapeutics Inc.	FREQ	Pharmaceutical Preparations (2834)	472324450

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1785288	L. David Lucchino	C/O Frequency Therapeutics, Inc. 19 Presidential Way, 2Nd Floor Woburn MA 01801	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-14	13,514	$0.61	337,314	No	4	M	Direct
Common Stock	Disposition	2020-12-14	13,514	$35.12	323,800	No	4	S	Direct
Common Stock	Acquisiton	2020-12-15	6,411	$0.61	330,211	No	4	M	Direct
Common Stock	Acquisiton	2020-12-15	7,103	$0.61	337,314	No	4	M	Direct
Common Stock	Disposition	2020-12-15	9,014	$38.18	328,300	No	4	S	Direct
Common Stock	Disposition	2020-12-15	4,500	$38.83	323,800	No	4	S	Direct
Common Stock	Acquisiton	2020-12-16	13,514	$0.61	337,314	No	4	M	Direct
Common Stock	Disposition	2020-12-16	13,514	$40.00	323,800	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Disposition	2020-12-14	13,514	$0.00	13,514	$0.61
Common Stock	Stock Option	Disposition	2020-12-15	6,411	$0.00	6,411	$0.61
Common Stock	Stock Option	Disposition	2020-12-15	7,103	$0.00	7,103	$0.61
Common Stock	Stock Option	Disposition	2020-12-16	13,514	$0.00	13,514	$0.61

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,324	2027-06-28	No	4	M	Direct
3,913	2027-06-28	No	4	M	Direct
303,544	2028-05-21	No	4	M	Direct
290,030	2028-05-21	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $35.08 to $35.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $37.5 to $38.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $38.505 to $39.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021.
The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022.